In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): Immunohistological evidence

B. Falini, L. Flenghi, L. Fedeli, M. K. Broe, C. Bonino, H. Stein, H. Durkop, B. Bigerna, G. Barbabietola, S. Venturi, F. Aversa, G. Pizzolo, A. Bartoli, S. Pileri, E. Sabattini, R. Palumbo, M. F. Martelli

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The ability of the Ber-H2 (CD30) monoclonal antibody (mAb) to target in vivo Hodgkin (H) and Reed-Sternberg (R-S) cells was investigated in six patients with advanced Hodgkin's disease (HD). The patients were injected with scaled-up quantities of 'cold' Ber-H2 mixed-up to a small dose of 131I-labelled Ber-H2, and in vivo binding of the antibody to H and R-S cells was assessed by immunohistological analysis of tumour biopsies and immunoscintigraphy. Only 50% of tumour sites were imaged at scintigraphy by the 131I-labelled Ber-H2. In contrast, immunohistological studies on tissue biopsies, taken 24-72 h following the mAb injection, showed that H and R-S cells in all tumour sites, including those that were not imaged by immunoscintigraphy, were specifically and strongly labelled in vivo by the injected Ber-H2, at a dose as low as 30-50 mg of antibody. In vivo binding of a single dose of Ber-H2 mAb to H and R-S cells did not result in any anti-tumour effect. The excellent in vivo targeting of H and R-S cells with the Ber-H2 mAb may have been the result of multiple favourable factors, including: (a) the restricted expression of the CD30 antigen in normal human tissues; (b) the low level of soluble CD30 in the serum of our patients; and (c) the high affinity of the Ber-H2 mAb for the CD30 molecule. The immunohistological results presented in this study provide a strong argument for using the Ber-H2 mAb as a carrier for delivering cytotoxic agents (isotopes or toxins) to neoplastic cells of HD refractory to conventional therapy.

Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalBritish Journal of Haematology
Volume82
Issue number1
Publication statusPublished - 1992

Fingerprint

Reed-Sternberg Cells
Hodgkin Disease
Monoclonal Antibodies
Neoplasms
CD30 Antigens
Biopsy
Antibodies
Cytotoxins
Isotopes
Radionuclide Imaging
Injections
Serum

ASJC Scopus subject areas

  • Hematology

Cite this

Falini, B., Flenghi, L., Fedeli, L., Broe, M. K., Bonino, C., Stein, H., ... Martelli, M. F. (1992). In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): Immunohistological evidence. British Journal of Haematology, 82(1), 38-45.

In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30) : Immunohistological evidence. / Falini, B.; Flenghi, L.; Fedeli, L.; Broe, M. K.; Bonino, C.; Stein, H.; Durkop, H.; Bigerna, B.; Barbabietola, G.; Venturi, S.; Aversa, F.; Pizzolo, G.; Bartoli, A.; Pileri, S.; Sabattini, E.; Palumbo, R.; Martelli, M. F.

In: British Journal of Haematology, Vol. 82, No. 1, 1992, p. 38-45.

Research output: Contribution to journalArticle

Falini, B, Flenghi, L, Fedeli, L, Broe, MK, Bonino, C, Stein, H, Durkop, H, Bigerna, B, Barbabietola, G, Venturi, S, Aversa, F, Pizzolo, G, Bartoli, A, Pileri, S, Sabattini, E, Palumbo, R & Martelli, MF 1992, 'In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): Immunohistological evidence', British Journal of Haematology, vol. 82, no. 1, pp. 38-45.
Falini, B. ; Flenghi, L. ; Fedeli, L. ; Broe, M. K. ; Bonino, C. ; Stein, H. ; Durkop, H. ; Bigerna, B. ; Barbabietola, G. ; Venturi, S. ; Aversa, F. ; Pizzolo, G. ; Bartoli, A. ; Pileri, S. ; Sabattini, E. ; Palumbo, R. ; Martelli, M. F. / In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30) : Immunohistological evidence. In: British Journal of Haematology. 1992 ; Vol. 82, No. 1. pp. 38-45.
@article{71722fb2db684d53ac8caf05269b73a5,
title = "In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): Immunohistological evidence",
abstract = "The ability of the Ber-H2 (CD30) monoclonal antibody (mAb) to target in vivo Hodgkin (H) and Reed-Sternberg (R-S) cells was investigated in six patients with advanced Hodgkin's disease (HD). The patients were injected with scaled-up quantities of 'cold' Ber-H2 mixed-up to a small dose of 131I-labelled Ber-H2, and in vivo binding of the antibody to H and R-S cells was assessed by immunohistological analysis of tumour biopsies and immunoscintigraphy. Only 50{\%} of tumour sites were imaged at scintigraphy by the 131I-labelled Ber-H2. In contrast, immunohistological studies on tissue biopsies, taken 24-72 h following the mAb injection, showed that H and R-S cells in all tumour sites, including those that were not imaged by immunoscintigraphy, were specifically and strongly labelled in vivo by the injected Ber-H2, at a dose as low as 30-50 mg of antibody. In vivo binding of a single dose of Ber-H2 mAb to H and R-S cells did not result in any anti-tumour effect. The excellent in vivo targeting of H and R-S cells with the Ber-H2 mAb may have been the result of multiple favourable factors, including: (a) the restricted expression of the CD30 antigen in normal human tissues; (b) the low level of soluble CD30 in the serum of our patients; and (c) the high affinity of the Ber-H2 mAb for the CD30 molecule. The immunohistological results presented in this study provide a strong argument for using the Ber-H2 mAb as a carrier for delivering cytotoxic agents (isotopes or toxins) to neoplastic cells of HD refractory to conventional therapy.",
author = "B. Falini and L. Flenghi and L. Fedeli and Broe, {M. K.} and C. Bonino and H. Stein and H. Durkop and B. Bigerna and G. Barbabietola and S. Venturi and F. Aversa and G. Pizzolo and A. Bartoli and S. Pileri and E. Sabattini and R. Palumbo and Martelli, {M. F.}",
year = "1992",
language = "English",
volume = "82",
pages = "38--45",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30)

T2 - Immunohistological evidence

AU - Falini, B.

AU - Flenghi, L.

AU - Fedeli, L.

AU - Broe, M. K.

AU - Bonino, C.

AU - Stein, H.

AU - Durkop, H.

AU - Bigerna, B.

AU - Barbabietola, G.

AU - Venturi, S.

AU - Aversa, F.

AU - Pizzolo, G.

AU - Bartoli, A.

AU - Pileri, S.

AU - Sabattini, E.

AU - Palumbo, R.

AU - Martelli, M. F.

PY - 1992

Y1 - 1992

N2 - The ability of the Ber-H2 (CD30) monoclonal antibody (mAb) to target in vivo Hodgkin (H) and Reed-Sternberg (R-S) cells was investigated in six patients with advanced Hodgkin's disease (HD). The patients were injected with scaled-up quantities of 'cold' Ber-H2 mixed-up to a small dose of 131I-labelled Ber-H2, and in vivo binding of the antibody to H and R-S cells was assessed by immunohistological analysis of tumour biopsies and immunoscintigraphy. Only 50% of tumour sites were imaged at scintigraphy by the 131I-labelled Ber-H2. In contrast, immunohistological studies on tissue biopsies, taken 24-72 h following the mAb injection, showed that H and R-S cells in all tumour sites, including those that were not imaged by immunoscintigraphy, were specifically and strongly labelled in vivo by the injected Ber-H2, at a dose as low as 30-50 mg of antibody. In vivo binding of a single dose of Ber-H2 mAb to H and R-S cells did not result in any anti-tumour effect. The excellent in vivo targeting of H and R-S cells with the Ber-H2 mAb may have been the result of multiple favourable factors, including: (a) the restricted expression of the CD30 antigen in normal human tissues; (b) the low level of soluble CD30 in the serum of our patients; and (c) the high affinity of the Ber-H2 mAb for the CD30 molecule. The immunohistological results presented in this study provide a strong argument for using the Ber-H2 mAb as a carrier for delivering cytotoxic agents (isotopes or toxins) to neoplastic cells of HD refractory to conventional therapy.

AB - The ability of the Ber-H2 (CD30) monoclonal antibody (mAb) to target in vivo Hodgkin (H) and Reed-Sternberg (R-S) cells was investigated in six patients with advanced Hodgkin's disease (HD). The patients were injected with scaled-up quantities of 'cold' Ber-H2 mixed-up to a small dose of 131I-labelled Ber-H2, and in vivo binding of the antibody to H and R-S cells was assessed by immunohistological analysis of tumour biopsies and immunoscintigraphy. Only 50% of tumour sites were imaged at scintigraphy by the 131I-labelled Ber-H2. In contrast, immunohistological studies on tissue biopsies, taken 24-72 h following the mAb injection, showed that H and R-S cells in all tumour sites, including those that were not imaged by immunoscintigraphy, were specifically and strongly labelled in vivo by the injected Ber-H2, at a dose as low as 30-50 mg of antibody. In vivo binding of a single dose of Ber-H2 mAb to H and R-S cells did not result in any anti-tumour effect. The excellent in vivo targeting of H and R-S cells with the Ber-H2 mAb may have been the result of multiple favourable factors, including: (a) the restricted expression of the CD30 antigen in normal human tissues; (b) the low level of soluble CD30 in the serum of our patients; and (c) the high affinity of the Ber-H2 mAb for the CD30 molecule. The immunohistological results presented in this study provide a strong argument for using the Ber-H2 mAb as a carrier for delivering cytotoxic agents (isotopes or toxins) to neoplastic cells of HD refractory to conventional therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026774327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026774327&partnerID=8YFLogxK

M3 - Article

C2 - 1329918

AN - SCOPUS:0026774327

VL - 82

SP - 38

EP - 45

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -